Authors
Loading...
Observational analysis shows somatic mutations lower cumulative incidence of treatment responses in chronic myeloid leukemia patients, indicating challenges with asciminib efficacy.
Kuzmina et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: